Development of a new mutation in EGFR leads to drug resistance in non-small cell lung cancer

Samankaltaisia teoksia

• Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer
  Tekijä: Takayuki Kosaka, et al.
  Julkaistu: (2011-01-01)
• Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer
  Tekijä: Kosaka, Takayuki, et al.
  Julkaistu: (2011)
• Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
  Tekijä: Leonetti, Alessandro, et al.
  Julkaistu: (2019)
• Systemic treatment of EGFR-mutated non-small cell lung cancer
  Tekijä: Rafał Ł. Czyżykowski, et al.
  Julkaistu: (2025-10-01)
• Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib
  Tekijä: Costa, Daniel B., et al.
  Julkaistu: (2008)